In 2012, approximately 37% of the adults in America had prediabetes, and almost 90% of them didn't realize it. The importance of intervention/education by community pharmacists cannot be overestimated.
The Americans with Disabilities Act of 1990 (ADA) provides a general legal framework for access of individuals with disabilities to public places and also for accommodating employees with disabilities in the workplace. Although the ADA contains very specific guidance for physical accommodations, such as wheelchair access, it provides little guidance relevant to workers with conditions such as diabetes.
American Diabetes Association Scientific Sessions in San Francisco, showed that investigational, non-insulin, once-weekly dulaglutide 1.5 mg provided significant blood glucose control for patients with type 2 diabetes.
LY2963016 insulin glargine has a similar safety and efficacy profile to currently marketed insulin glargine, according to data recently presented the American Diabetes Association (ADA) Scientific Sessions in San Francisco.
In a 52-week study of obese adults with type 2 diabetes on high insulin doses with or without metformin, adding empagliflozin to multiple daily insulin injections significantly reduced blood glucose and body weight with lower insulin doses compared with placebo, according to data recently presented at the American Diabetes Association (ADA) Scientific Sessions in San Francisco.
In a 2-year study, empagliflozin as add-on to metformin demonstrated significantly greater decreases in hemoglobin A1c (a measure of average blood glucose over the past 2 to 3 months), body weight and blood pressure compared with glimepiride as add-on to metformin in adults with type 2 diabetes.